News|Articles|May 4, 2026

AACE 2026 Recap: 5 Key Presentations to Know

Catch up on any data and perspectives presented at the American Association of Clinical Endocrinology Annual Meeting 2026.

The American Association of Clinical Endocrinology (AACE) Annual Meeting 2026, in Las Vegas, Nevada, brought together a number of key clinicians to share updates and advancements in everything from obesity and diabetes to thyroid health and growth hormone deficiencies. Trials like CAHtalyst Adult and discussions on topics like GLP-1s in type 1 diabetes (T1D) took center stage over the 3-day meeting.

Related to this article

September 18th, 2026

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's recent approval of Bayer's finerenone in concomitant CKD and T1D.

September 15th, 2026

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Beta Bionics' new insulin patch pump, expected to be commercialized in Q1 2027.

September 10th, 2026

Diana Isaacs, PharmD, and Natalie Bellini, DNP, unpack tirzepatide's new CV indication and the STAREE statin trial in older adults.

September 17th, 2026

The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.

September 14th, 2026

Beta Bionics plans to launch Mint through the pharmacy channel in the first quarter of 2027.

September 16th, 2026

In this Q&A, Leon Kircik, MD, discusses challenging watch-and-wait for molluscum contagiosum with berdazimer gel, 10.3%, at LEADderm 2026.

September 15th, 2026

Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.

September 14th, 2026

Wechsler, of National Jewish Health discusses how oral STAT6 degraders like KT-621 could offer a mechanistically distinct treatment option.